Sorafenib in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide with approximately 500,000 new cases per year, ranking as the third cause of cancer deaths. Until the very recent past no systemic therapy was available for patients with advanced HCC. However, advances achieved in the unde...

Full description

Saved in:
Bibliographic Details
Published in:Clinical Medicine Insights: Therapeutics 2009-01, Vol.1, p.277
Main Authors: Bajetta, Emilio, Procopio, Giuseppe, Colombo, Andrea, Guadalupi, Valentina, Verzoni, Elena, Pietrantonio, Filippo, Pusceddu, Sara, Manzoni, Mariangela, Gevorgyan, Arpine, Buzzoni, Roberto
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide with approximately 500,000 new cases per year, ranking as the third cause of cancer deaths. Until the very recent past no systemic therapy was available for patients with advanced HCC. However, advances achieved in the understanding of the molecular cancer biology and the subsequent introduction of molecularly targeted agents have disclosed promising and interesting possibilities for the treatment of this highly vascularized tumor in which the inhibition of angiogenesis is likely to represent the main potential therapeutic target. In this regard, sorafenib, an oral multikinase inhibitor endowed with significant activity against several tyrosine-kinase receptors involved in blood vessel development, has shown to be very active in the treatment of advanced HCC. This review makes a survey of pharmacology, mode of action, pharmacokinetics, clinical value and safety of sorafenib when employed in the treatment of advanced HCC.
ISSN:1179-559X
DOI:10.4137/CMT.S2314